Published in Nat Rev Gastroenterol Hepatol on March 08, 2011
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
Role of intestinal inflammation as an early event in obesity and insulin resistance. Curr Opin Clin Nutr Metab Care (2011) 1.19
A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer (2013) 1.15
Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol (2014) 1.11
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol (2014) 1.04
Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Carcinogenesis (2012) 1.02
Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. Ann Oncol (2012) 1.00
Alternative origins of stroma in normal organs and disease. Stem Cell Res (2011) 0.94
Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev (2015) 0.90
Benign, premalignant, and malignant lesions encountered in bariatric surgery. JSLS (2013) 0.90
Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer. Int J Colorectal Dis (2013) 0.88
Insulin receptor isoform switching in intestinal stem cells, progenitors, differentiated lineages and tumors: evidence that IR-B limits proliferation. J Cell Sci (2013) 0.87
Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet (2013) 0.85
The tumor microenvironment in esophageal cancer. Oncogene (2016) 0.83
ω3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients. PLoS One (2013) 0.83
Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev (2013) 0.83
Increased Obesity-Associated Circulating Levels of the Extracellular Matrix Proteins Osteopontin, Chitinase-3 Like-1 and Tenascin C Are Associated with Colon Cancer. PLoS One (2016) 0.79
Diet-induced obesity and ethanol impair progression of hepatocellular carcinoma in a mouse mesenteric vein injection model. Surg Endosc (2012) 0.78
Angiopoietin-like protein ANGPTL2 gene expression is correlated with lymph node metastasis in lung cancer. Oncol Lett (2012) 0.78
How normal is the liver in which the inflammatory type hepatocellular adenoma develops? Int J Hepatol (2012) 0.78
Expression of TMEM207 in Colorectal Cancer: Relation between TMEM207 and Intelectin-1. J Cancer (2016) 0.76
Diet and the Gut. Middle East J Dig Dis (2016) 0.76
Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. Br J Cancer (2016) 0.75
Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. Br J Cancer (2016) 0.75
Clinical and Oncological Value of Preoperative BMI in Gastric Cancer Patients: A Single Center Experience. Gastroenterol Res Pract (2015) 0.75
Acanthosis nigricans associated with morbid obesity and colorectal adenocarcinoma. Case Rep Dermatol Med (2012) 0.75
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res (1998) 50.73
Microbial ecology: human gut microbes associated with obesity. Nature (2006) 36.98
Inflammation and metabolic disorders. Nature (2006) 33.33
The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A (2004) 26.56
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Inflammation, stress, and diabetes. J Clin Invest (2005) 17.11
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 14.25
Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 14.12
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med (2009) 11.28
Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med (2009) 9.71
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A (2007) 9.71
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 8.77
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med (1993) 7.67
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev (2000) 6.54
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer (2005) 6.06
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (2010) 5.44
Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med (1995) 5.42
Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr (2001) 5.16
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology (2004) 4.89
Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med (2005) 4.52
Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol (2008) 4.44
Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology (2007) 3.94
Gastric cancer epidemiology and risk factors. J Clin Epidemiol (2003) 3.94
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA (2009) 3.86
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr (2007) 3.66
Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin (2001) 3.65
Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes (2010) 3.39
Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer (2006) 3.27
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev (2007) 3.16
Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol (2009) 3.14
A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control (2001) 3.13
Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract (2004) 2.95
Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med (2010) 2.94
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol (2007) 2.79
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst (2006) 2.77
Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes (2010) 2.70
Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA (2003) 2.68
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ (2010) 2.64
Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery (2009) 2.64
Worldwide trends in mortality from biliary tract malignancies. BMC Cancer (2002) 2.61
Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun (2006) 2.56
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol (2005) 2.51
The metabolic syndrome: A high-risk state for cancer? Am J Pathol (2006) 2.46
Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut (2005) 2.37
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.34
Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut (2006) 2.28
Cholecystectomy for asymptomatic gallstones can reduce gall bladder cancer mortality in northern Indian women. Indian J Gastroenterol (2006) 2.27
Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer (2007) 2.23
Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer (2007) 2.22
Central adiposity and risk of Barrett's esophagus. Gastroenterology (2007) 2.20
Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis (2008) 2.19
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer (2003) 2.19
Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology (1998) 2.15
Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 2.13
Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol (2003) 2.12
Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ (2010) 2.01
Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol (2008) 1.97
Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer (2010) 1.93
Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol (2006) 1.90
Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res (1995) 1.89
Obesity and colon cancer: does leptin provide a link? Int J Cancer (2004) 1.89
Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med (2010) 1.88
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol (2004) 1.86
BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord (2004) 1.85
Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control (1996) 1.82
Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer (2004) 1.79
Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol (2009) 1.79
Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther (2010) 1.76
Prevalence of gallbladder polyps among apparently healthy Japanese: ultrasonographic study. Am J Gastroenterol (1992) 1.74
Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol (2007) 1.73
C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer (2008) 1.71
Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol (2002) 1.70
Body mass index and Barrett's oesophagus in women. Gut (2009) 1.70
Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann Thorac Surg (2009) 1.69
Epidemiology of esophageal adenocarcinoma. J Surg Oncol (2005) 1.69
Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci (2008) 1.69
Impact of obesity on surgical outcomes after colorectal resection. Am J Surg (2000) 1.67
Colorectal cancer screening disparities related to obesity and gender. J Gen Intern Med (2004) 1.66
Body mass index: a marker for significant colorectal neoplasia in a screening population. J Clin Gastroenterol (2007) 1.65
Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol (2006) 1.65
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol (2008) 1.64
Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) (2009) 1.64
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology (2002) 1.63
Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci (2010) 1.62
Plasma adiponectin and gastric cancer. Clin Cancer Res (2005) 1.62
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol (2010) 1.61
The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm (2010) 1.59
Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology (2005) 1.58
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut (2010) 2.23
Increased risk of colorectal cancer after obesity surgery. Ann Surg (2013) 2.17
Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology (2005) 2.05
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis (2002) 1.20
Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood (2003) 1.14
MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J Pathol (2013) 1.07
FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS One (2012) 0.98
Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Neoplasia (2010) 0.95
The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology (2003) 0.94
Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol (2002) 0.89
Increased colorectal epithelial cell proliferation and crypt fission associated with obesity and roux-en-Y gastric bypass. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing? Digestion (2012) 0.86
Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. Int J Cancer (2014) 0.83
Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene (2002) 0.82
Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastases. BMC Cancer (2013) 0.80
High-frequency ultrasound for in vivo measurement of colon wall thickness in mice. Ultrasound Med Biol (2012) 0.79
Colonoscopy for colonic wall thickening at computed tomography: a worthwhile pursuit? Surg Endosc (2011) 0.79
Folic Acid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease : A Systematic Review and Meta-Analysis. J Clin Gastroenterol (2016) 0.79
Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue. Angiogenesis (2006) 0.78
Expression of prostaglandin D2 receptors DP1 and DP2 by human colorectal cancer cells. Cancer Lett (2004) 0.78
Analysis of cyclooxygenase expression in human colorectal adenomas. Dis Colon Rectum (2002) 0.77
Altered intestinal epithelium-associated lymphocyte repertoires and function in ApcMin/+ mice. Int J Oncol (2011) 0.75
Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass. Obesity (Silver Spring) (2014) 0.75
Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations. Carcinogenesis (2013) 0.75